aPALACE 1-3 pooled analysis. Data as observed; includes all patients who received OTEZLA 30 mg BID, regardless of whether they were initially randomized to OTEZLA 30 mg BID or placebo patients who were re-randomized to OTEZLA at week 16 or week 24.
Patients treated with OTEZLA 30 mg BID achieved
significantly greater improvement vs placebo in MASES (enthesitis)
score (mean change of -1.3 vs 0.9, P<0.05) at week 242†
*Pooled patient data from PALACE 1-3; includes all randomized patients with preexisting enthesopathy (baseline MASES score >0; n = 945). Resolution was defined as a MASES score of 0.
†LOCF; for patients who qualified for early escape at week 16, the week 16 value was carried forward.
BID, twice daily; LOCF, last observation carried forward; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy.
aLAPIS-PsA study, interim analysis at 4 months. Data as observed among patients with value available at specified time point.
In a real-world setting, OTEZLA led to complete resolution of enthesitis3†
*Among patients with an LEI >0 at baseline (n = 49/111, 44.5%).
†Defined as LEI = 0.
LAPIS-PsA, Study of Apremilast Use in Patients with Psoriatic Arthritic in Practice Conditions; LEI, Leeds Enthesitis Index.
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).